
Alnylam is the world’s leading RNA interference (RNAi) company, dedicated to transforming the lives of patients through innovative medicines. As Alnylam continues to expand its global development and regulatory footprint, Regulatory Sciences supports increasing portfolio complexity, global regulatory engagement, and heightened expectations for data quality, compliance, and operational efficiency.
The Director, Regulatory Technology & Medical Writing Systems will play a critical role in shaping and executing the technology strategy supporting Regulatory Affairs, Regulatory Operations, and Medical Writing. This role serves as the primary business technology functional leader for these teams, ensuring that platforms, data, content capabilities, and digital workflows enable compliant, efficient, inspection-ready, and insight-driven regulatory and medical writing operations across the product lifecycle.
Success in this role requires strong development-domain business acumen, technical fluency across regulated platforms, and the ability to translate functional priorities into a practical technology roadmap. The leader will be expected to connect strategy to execution—partnering with business stakeholders, enterprise Technology, Data, Quality, Security, and vendor teams to deliver scalable, compliant, and user-centered solutions.
Rather than serving as a single-system product owner, this role provides functional technology leadership across the broader Regulatory and Medical Writing capability landscape. The Director will shape priorities, connect process and data needs across platforms, and work through dedicated product owners, application teams, vendors, and enterprise technology partners to ensure solutions advance the end-to-end business strategy.
We are the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded based on Nobel Prize-winning science, our work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of RNAi therapeutics possible. Guided by core values like fierce innovation, purposeful urgency, and passion for excellence, our open and inclusive culture drives everything we do. We are proud to be globally recognized as a top employer, where people feel valued and breakthrough thinking flourishes.
About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.
Before applying, please review Alnylam's Candidate Privacy Notice regarding how Alnylam handles Personal Data you provide with your application for employment.
#LI-LN1
The pay range below reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on a number of factors including, but not limited to, relevant experience, skills, and education. This role is eligible for an annual short-term incentive award (e.g., bonus or sales incentive) and an annual long-term incentive award (e.g., equity).
Alnylam’s robust Total Rewards package is designed to support your overall health and well-being. We offer comprehensive benefits including medical, dental, and vision coverage, life and disability insurance, a lifestyle reimbursement program, flexible spending and health savings accounts and a 401(k)with a generous company match. Eligible employees enjoy paid time off, wellness days, holidays, and two company-wide recharge breaks. We also offer generous family resources and leave. Our commitment to your well-being reflects our belief that caring for our people fuels the impact we create together.
Learn more about these and additional benefits offered by Alnylam by visiting the Benefits section of the Careers website: https://www.alnylam.com/careers
U.S. Pay Range
$187,400—$253,600 USD

SILENCE DISEASE. AMPLIFY LIFE.™
Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.
Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases.
We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024).
We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America.
See our social media community guidelines: https://bit.ly/2FcRhJy.
Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861
Fraudulent Recruitment Activity
Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."